Maheux, Pierre

The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein

Wolever, T. M., Gibbs, A. L., Mehling, C., Chiasson, J.-L., Connelly, P. W., Josse, R. G., Leiter, L. A., Maheux, P., Rabasa-Lhoret, R., Rodger, N. W., et al. (2008) · The American Journal of Clinical Nutrition

Diet and metabolism studiesDiabetes Treatment and Management

Cited by 333

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Ray, K. K., Troquay, R. P. T., Visseren, F. L. J., Leiter, L. A., Scott Wright, R., Vikarunnessa, S., Talloczy, Z., Zang, X., Maheux, P., Lesogor, A., et al. (2023) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 328

Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study

de Pablos‐Velasco, P., Parhofer, K. G., Bradley, C., Eschwège, E., Gönder-Frederick, L., Maheux, P., Wood, I., & Simon, D. (2014) · Clinical Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 218

Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue‐specific manner

Panarotto, D., Rémillard, P., Bouffard, L., & Maheux, P. (2002) · European Journal of Clinical Investigation

Lipid metabolism and disordersLipid metabolism and biosynthesis

Cited by 137

Acarbose in the treatment of elderly patients with type 2 diabetes

Josse, R. G., Chiasson, J.-L., Ryan, E. A., Lau, D. C. W., Ross, S. A., Yale, J.-F., Leiter, L. A., Maheux, P., Tessier, D., Wolever, T. M. S., et al. (2003) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 110

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright, R. S., Raal, F. J., Koenig, W., Landmesser, U., Leiter, L. A., Vikarunnessa, S., Lesogor, A., Maheux, P., Talloczy, Z., Zang, X., et al. (2024) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 102

Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial

Raal, F., Durst, R., Bi, R., Talloczy, Z., Maheux, P., Lesogor, A., Kastelein, J. J. P., & on behalf of the ORION-5 Study Investigators (2024) · Circulation

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 96

Efficacy and Safety of Inclisiran in Asian Patients

Huo, Y., Lesogor, A., Lee, C. W., Chiang, C.-E., Mena-Madrazo, J., Poh, K. K., Jeong, M. H., Maheux, P., Zhang, M., Wei, S., et al. (2024) · JACC: Asia

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 31

Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15

Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 26